Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.

Abstract

BACKGROUND/AIM:

Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma.

PATIENTS AND METHODS:

Thirty-four patients received NPLD 40 mg/m(2) (d1) and ifosfamide 3 g/m(2)/day (d1-3) every three weeks as first-line therapy of metastatic soft tissue sarcoma. The treatment was planned for a maximum of six cycles.

RESULTS:

The objective response (OR) rate among response-assessable patients was 55.9%. The median progression-free survival (PFS) was 4.2 months and the median overall survival (OS) was 11.2 months. Symptomatic grade 3 cardiotoxicity occurred in one patient (3%).

CONCLUSION:

The combination of NPLD and ifosfamide reported in a population of metastatic soft tissue sarcoma patients at risk for developing heart failure encourage antitumour activity, similar to that of classical doxorubicin.

• Authors: Rita De Sanctis, Alexia Bertuzzi, Umberto Basso, Alessandro Comandone, Silvia Marchetti, Andrea Marrari, Piergiuseppe Colombo, Romano Fabio Lutman, Laura Giordano, Armando Santoro
• Journal: Anticancer research (Anticancer Res) Vol. 35 Issue 1 Pg. 543-7 (Jan 2015) ISSN: 1791-7530 [Electronic] Greece
• PMID: 25550600 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin
• Ifosfamide

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Disease-Free Survival
• Doxorubicin (administration & dosage, analogs & derivatives)
• Drug Administration Schedule
• Female
• Humans
• Ifosfamide (administration & dosage)
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Polyethylene Glycols (administration & dosage)
• Sarcoma (drug therapy, mortality, secondary)
• Treatment Outcome